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The routine haematological and biochemical tests remained
unchanged in both groups after treatment, and there were no
local reactions to the injection of either agent.
Methotrexate is theoretically an attractive agent for intra-
articular use in chronic synovitis since it would be expected to
be active locally and is also safer than most other cytotoxic
agents used in the treatment of inflammatory arthropathies.
However, in this trial we have not found methotrexate used as
a single 5 mg intra-articular injection along with 50 mg hydro-
cortisone to be superior to hydrocortisone alone, using objec-
tive tests of knee assessment under blind conditions. It must be
stressed, however, that the patients included in this trial had
active rheumatoid disease with long-standing synovitis of the
knee complicated by secondary mechanical changes; the aver-
age erythrocyte-sedimentation rate in both groups exceeded 50
mm in the first hour, and knee radiography showed moderate
destructive features. Maybe this type of patient is unlikely to
respond permanently to any form of local medical treatment
but they are a common and difficult therapeutic problem, since
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ACID-BASE DIAGRAMS
SIR,&mdash;Any student of acid-base balance would welcome in-
novations which make the teaching of acid-base principles and
the management of acid-base disorders easier. Dr Grogono and
his colleagues (Sept. 4, p. 499) claim that their acid-base dia-
gram does just this. This design, however, needs closer analysis
before uncritical acceptance.
Grogono et al. claim that their method avoids the concept
of "base excess". Yet they introduce the term "metabolic aci-
dosis" and allow a minus or negative form of this. Moreover,
their values are remarkably close to base excess derived from
a diagram in a paper’ they criticise for having used in-vitro
behaviour of blood to represent in-vivo disturbances.
If you take the data obtained by Albert et al. in 60 patients
with uncomplicated and untreated metabolic acidosis and sub-
tract any observed HC03- concentration from an arbitrary
normal of 25 mmol/1, you get values within 1 or 2 mmol/1 of
the "metabolic acidosis" values obtained from the new chart.
Similarly, from data on chronic respiratory acidosis in man,3
the 95% confidence band for Pco2 of 70 mm Hg encompasses
a pH range of 7.28-7-40 and [HCO3&mdash;] of 33-44 mmol/l.
Simply subtracting [HCO3&mdash;] from 25, gives values strikingly
close to the "metabolic acidosis" values of -6 and -18, respec-
tively, from the new diagram. Where lies the advantage of this
method over knowing that, to correct acid-base abnormalities,
PC02 should tend toward 40 mm Hg, [HCO3&mdash;] toward 25
mmol/1, and pH toward 7.4, and that the degree of metabolic
acidosis may be estimated by subtracting observed [HCO3&mdash;]
from 25? In either approach one still needs a careful analysis
of patient history and clinical findings to work out how he
arrived at his state of disorder and guide his return to normal,
principles succinctly set forth by Schwartz and Relman many
years ago.4
The data of Garella et al.6 suggest that the 0.3 x body-
weight formula for calculating HC03 replacement therapy, as
used by the Syracuse workers, may at times greatly underesti-
mate the actual amount required, but their cautious approach
is probably generally warranted.
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IMMUNISING AGAINST RECEPTORS FOR ANTIGEN
SIR,&mdash;In your editorial (Sept. 4, p. 505) you review the sub-
ject of anti-idiotypic antibodies and the role they play in im-
mune regulation and control with particular reference to
transplantation immunology and autoimmunity. Another
aspect is the appearance of similar anti-receptor-site cr anu-
idiotypic antibodies in malignancy.
You emphasise the importance of producing anti-idiotvpic
antibodies and their mechanism in suppressing immune reacti-
vity against the particular antigen to which the idiotype was
directed. We have found auto anti-idiotypic antibodies in the
sera of patients with malignant melanoma, and have offered
this as an explanation for the elimination of a particular anti-
melanoma antibody. 1 Similar anti-antibodies have been
demonstrated in animal models,2 particularly the myeloma-
lymphoma group. For instance, antisera produced against
monoclonal IgM on the surface of a spontaneous lymphoma in
NZB/NZW F, mice could confer protective immunity against
the neoplasm.3 In addition antibody against the antigen rece;r
tor in plasmacytoma of Balb/c mice prolongs the survival of
these animals.4
Further evidence indicates that auto anti-idiotypic anti-
bodies did occurs and a dual role, in both suppression and ac-
tivation of specific immune responses, has been suggested.6
We have demonstrated anti-antibodies against tumour-spe-
cific antibodies in the serum not only in melanoma but also in
unrelated human malignancies,7 especially in patients with
prostatic carcinoma after cryosurgery.8 The antibody directed
against the prostatic carcinoma was transient, and we find that
immunoglobulin in the negative sera from these patients speci-
fically reacts with the tumour-antibody-positive sera, taken at
a different time. The role of such anti-idiotypic antibodies is
fundamental to the process of immune regulation.’ 10
The events seen in autoimmunity, chronic parasitic infec-
tions, and malignancy are, therefore, likely to be reflections of
derangement in immune regulation," and the presence of anti-
idiotypic antibodies may be potentially important not only
in therapy, as suggested in your editorial, but also as a means
of indicating failure of immune control.12 The role of immune
complexes composed of tumour antigens and anti-tumour znti-
bodies in malignancy has received much attention. The possi-
bility, however, that anti-antibody complexes might occur and
be of some importance has been suggested, and demonstrated
in our laboratories.12 The importance of this in malignancy is
considerable, both for prognosis and for immunotherapy, the
reverse of the situation pertaining to transplantation. The fact
that auto anti-idiotypic antibodies can occur makes therapy
more feasible than you suggest because complex procedures
and Freund’s adjuvant would not necessarily be needed. It is
important to realise that these mechanisms may strongly link
together approaches to the studies of transplantation, autoim-
munity, and malignancy.
McGill University Cancer Research Unit,
McIntyre Medical Sciences Building,
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